In vivo activation of tumor-specific cytotoxic T cells
AssigneeThe Scripps Research Institute
InventorLinda A. Sherman
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions of activating cytotoxic T lymphocytes (CTLs) in vivo with specificity for particular antigenic peptides, and to methods and compositions of using activated CTLs in vivo for the treatment of a variety of disease conditions. In some preferred embodiments, the invention provides methods of employing a polypeptide of the amino acid sequence VMAGVGSPYV to specifically activating CTLs in subjects having a breast cancer overexpressing a Her-2/Neu protein, and methods of using the polypeptide to treat such subjects.
Claims16
A method of specifically activating cytotoxic T lymphocytes in an animal having a breast cancer that overexpresses a Her-2/Neu protein, the method comprising the step of administering the polypeptide of SEQ ID NO:12 to said animal, thereby activating cytotoxic T lymphocytes in the animal.
A method of treating a patient having a breast cancer overexpressing a Her-2/Neu protein, the method comprising the step of administering the polypeptide of the amino acid sequence VMAGVGSPYV (SEQ ID NO:12) to the patient, thereby treating the breast cancer in the patient.
Dependencies are inferred from the claim text.